GNFT

Genfit

3.91 USD
-0.09
2.25%
Updated Feb 7, 11:09 AM EST
1 day
-2.25%
5 days
5.68%
1 month
4.83%
3 months
-31.52%
6 months
-3.69%
Year to date
2.09%
1 year
9.83%
5 years
-77.00%
10 years
-82.36%
 

About: Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Employees: 167

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

57% more capital invested

Capital invested by funds: $296K [Q2] → $465K (+$169K) [Q3]

0.01% less ownership

Funds ownership: 0.16% [Q2] → 0.16% (-0.01%) [Q3]

43% less funds holding

Funds holding: 7 [Q2] → 4 (-3) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$13
232%
upside
Avg. target
$13
232%
upside
High target
$13
232%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
55% 1-year accuracy
90 / 163 met price target
232%upside
$13
Buy
Reiterated
7 Feb 2025

Financial journalist opinion

Based on 4 articles about GNFT published over the past 30 days

Neutral
GlobeNewsWire
21 hours ago
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure (ACLF) pipeline, with several clinical data readouts by end of 2025.
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
Neutral
GlobeNewsWire
1 week ago
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, and debt overhang resolution plan.
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
Neutral
GlobeNewsWire
1 week ago
GENFIT Announces 2025 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025.
GENFIT Announces 2025 Financial Calendar
Neutral
GlobeNewsWire
3 weeks ago
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Neutral
GlobeNewsWire
2 months ago
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today provided a corporate update ahead of The Liver Meeting 2024®2.
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
Neutral
GlobeNewsWire
3 months ago
GENFIT Reports Third Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2024 and revenue for the first nine months of 20241.
GENFIT Reports Third Quarter 2024 Financial Information
Negative
Benzinga
4 months ago
Top 4 Health Care Stocks That May Keep You Up At Night
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 4 Health Care Stocks That May Keep You Up At Night
Neutral
GlobeNewsWire
4 months ago
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. This follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on July 26, 2024 and the U.S. FDA Accelerated Approval on June, 10, 2024 .
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Neutral
GlobeNewsWire
6 months ago
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen's Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA.
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Neutral
GlobeNewsWire
7 months ago
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Charts implemented using Lightweight Charts™